Previous close | 5.03 |
Open | 5.10 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 4.90 - 5.10 |
52-week range | 4.29 - 14.45 |
Volume | |
Avg. volume | 411,754 |
Market cap | 4.503M |
Beta (5Y monthly) | 1.55 |
PE ratio (TTM) | N/A |
EPS (TTM) | -14.56 |
Earnings date | 09 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 15.47 |
-- Lovell is an approved supplier to the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) ---- Over 28,000 cases of multiple sclerosis (MS) are reported to the VA annually -- NEWTOWN, Pa., April 03, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced it has partnered with Lovell Government S
Helius Medical Technologies, Inc. (NASDAQ:HSDT) Q4 2023 Earnings Call Transcript March 28, 2024 Helius Medical Technologies, Inc. beats earnings expectations. Reported EPS is $-1.47, expectations were $-4.05. HSDT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank […]
-- Company to host call at 4:30pm today -- NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter and full year ended December 31, 2023. Fourth Quarter and Recent Business Updates Secured Healthcare Common Procedure Coding System (“HCPCS”) Level II codes for the Portable